Please Wait.....
Report
United Kingdom Drug Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 100 Pages I Mordor Intelligence
United Kingdom Drug Delivery Devices Market Analysis
The United Kingdom drug delivery devices market is valued at USD 8.92 billion in 2025 and is forecast to reach USD 12.79 billion by 2030, reflecting a 7.47% CAGR during 2025-2030. Growth is propelled by the National Health Service (NHS) drive for precision medicine, rising adoption of home-based care, and accelerated approval pathways that shorten time-to-market for innovative devices. Every 1% gain in adherence is estimated to save the NHS about GBP 500 million in avoided hospital admissions, keeping cost reduction at the center of procurement strategies. Post-Brexit regulation has shifted to UKCA marking, yet the new International Reliance procedure allows devices cleared in Australia, Canada, the European Union, or the United States to enter the United Kingdom drug delivery devices market more rapidly, sustaining the country's attractiveness for foreign innovators. Sustainability also matters: near-zero global-warming-potential (GWP) propellants in next-generation pressurised metered-dose inhalers (pMDIs) are helping manufacturers win NHS tenders while meeting carbon-reduction targets. A parallel surge in connected devices responds to medication non-adherence that costs the NHS roughly GBP 637 million each year.
United Kingdom Drug Delivery Devices Market Trends and Insights
Government initiatives for self-administration & homecare
An extra GBP 86 million added to the Disabled Facilities Grant in 2025 enables more patients to manage conditions at home, complementing the Pharmacy First scheme that now covers seven minor conditions at almost every community pharmacy. The NHS plan to distribute artificial-pancreas technology over five years exemplifies policy-driven demand for intuitive self-use systems. Such measures channel volume into the United Kingdom drug delivery devices market for pen injectors, wearable pumps, and inhalers designed for layperson operation.
Development and adoption of smart connected drug delivery devices
Connected devices are expected to post a doubt digit CAGR in United Kingdom healthcare through 2030 as electronic health-record coverage climbs toward 95% of NHS trusts. Smart inhalers reimbursed under the MedTech Funding Mandate and Bluetooth add-ons like DOSE for insulin pens show how IoT integration addresses non-adherence that leads to 22,000 premature deaths a year. The broad data backbone being built by the Digital Health and Care Plan lets these devices feed real-time dosing data directly into clinical workflows.
Stringent fragmented regulatory landscape coupled with post-Brexit challenges
Manufacturers must maintain both CE and UKCA certification until 2030, and the post-market-surveillance rules effective June 2025 widen the definition of a serious incident. Non-UK suppliers must appoint a Responsible Person, adding cost and complexity, although expansion of approved bodies and an International Reliance route offer partial relief.
Other drivers and restraints analyzed in the detailed report include:
Biologics pipeline growth driving advanced injectors demand / Increasing R&D investment / High development and manufacturing cost /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Injectable formats held 45.6% of the United Kingdom drug delivery devices market share in 2024. The prevalence of biologics and patient preference for self-injection explain this lead. Integration of sensors and wireless modules is turning prefilled pens into data-rich adherence tools. Over 2025-2030, implantable systems will post the fastest 10.86% CAGR as research centers such as OxCD3 advance ultrasound-triggered depots that release drugs over months.
The inhalation segment benefits from NHS decarbonisation targets, steering procurement toward pMDIs with near-zero GWP propellants. Transdermal patches are expanding as microneedle arrays improve permeability without needles. Nasal and ocular devices remain niche but attract specialised R&D funding, reflecting an overall diversification of the United Kingdom drug delivery devices market.
Injectables delivered 52.3% of revenue in 2024 and leverage NHS investment of GBP 204 million into modern aseptic hubs that raise throughput for large-volume syringes. Oral mucosal systems, however, are gaining ground with a 9.38% forecast CAGR thanks to muco-adhesive films that avoid first-pass metabolism and reach peak plasma levels within minutes.
The inhalation route benefits from sustainability mandates, while transdermal patches ride patient demand for painless options. Nasal administration promises direct brain delivery for neurological disorders, a white-space opportunity within the United Kingdom drug delivery devices market that could reshape therapy for Alzheimer's and Parkinson's. Ocular implants are moving from monthly injections to semestral inserts, easing clinic workload and improving adherence.
United Kingdom Drug Delivery Devices Market Report is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps, and More), Route of Administration (Injectable, Inhalational, Transdermal, and More), Application (Diabetes, Respiratory Diseases, Oncology, and More), and End User (Hospitals, Ambulatory Surgical Centers, and More). The Market and Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Pfizer / AstraZeneca / GlaxoSmithKline / Novartis / Roche / Solventum / Beckton Dickinson / Baxter / Ypsomed / Nemera / Gerresheimer / AptarGroup Inc. / Owen Mumford / Teva Pharmaceutical Industries / West Pharmaceutical Services / SHL Medical / ICU Medical / Terumo / Insulet / Tandem Diabetes Care /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Government Initiatives and Trends for Self-Administration & Homecare
4.2.2 Development and Adoption Smart Connected Drug Delivery Devices
4.2.3 Increasing Research and Development Initiatives and Support from Government
4.2.4 Biologics Pipeline Growth Driving Advanced Injectors Demand
4.2.5 Rising Prevalence and Incidence of Chronic and Infectious Diseases
4.2.6 Fast-Track Approvals for Combination Products Post-Brexit
4.3 Market Restraints
4.3.1 Post Brexit Challenges Related to Delays and Cost
4.3.2 High Development and Manufacturing Cost Coupled with Limited Domestic Clean-Room Manufacturing Capacity
4.3.3 Risk and Concerns Associatied with Different Devices
4.3.4 NHS Pricing and Rebate Pressure
4.4 Value / Supply-Chain Analysis
4.5 Regulatory and Technological Outlook
4.6 Porter's Five Forces Analysis
4.6.1 Bargaining Power of Suppliers
4.6.2 Bargaining Power of Buyers
4.6.3 Threat of New Entrants
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size and Growth Forecasts (Value-USD)
5.1 By Device Type
5.1.1 Injectable Delivery Devices
5.1.2 Inhalation Delivery Devices
5.1.3 Infusion Pumps
5.1.4 Transdermal Patches
5.1.5 Implantable Drug Delivery Systems
5.1.6 Ocular Inserts & Delivery Implants
5.1.7 Nasal & Buccal Delivery Devices
5.2 By Route of Administration
5.2.1 Injectable
5.2.2 Inhalation
5.2.3 Transdermal
5.2.4 Oral Mucosal (Buccal & Sublingual)
5.2.5 Ocular
5.2.6 Nasal
5.3 By Application
5.3.1 Diabetes
5.3.2 Respiratory Diseases
5.3.3 Oncology
5.3.4 Cardiovascular Diseases
5.3.5 Infectious Diseases
5.3.6 Neurological Disorders
5.3.7 Others
5.4 By End-User
5.4.1 Hospitals
5.4.2 Ambulatory Surgical Centres
5.4.3 Homecare Settings
5.4.4 Speciality Clinics
5.4.5 Others
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.4.1 Pfizer Inc.
6.4.2 AstraZeneca plc
6.4.3 GlaxoSmithKline plc
6.4.4 Novartis AG
6.4.5 F. Hoffmann-La Roche Ltd
6.4.6 Solventum
6.4.7 Becton, Dickinson and Company
6.4.8 Baxter International Inc.
6.4.9 Ypsomed AG
6.4.10 Nemera
6.4.11 Gerresheimer AG
6.4.12 AptarGroup Inc.
6.4.13 Owen Mumford Ltd.
6.4.14 Teva Pharmaceutical Industries Ltd.
6.4.15 West Pharmaceutical Services Inc.
6.4.16 SHL Medical
6.4.17 ICU Medical
6.4.18 Terumo Corporation
6.4.19 Insulet Corporation
6.4.20 Tandem Diabetes Care, Inc.
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security